| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Amortization of acquired intangible assets | NaN | NaN | 4 | 8 |
| Realized/unrealized loss in investment, related party | NaN | -1 | 1 | 2 |
| Net loss | -4,752 | 5,640 | -6,649 | -9,527 |
| Loss on debt extinguishment | NaN | 0 | 0 | 0 |
| Depreciation | NaN | NaN | 17 | 47 |
| Depreciation and amortization | 55 | 138 | NaN | NaN |
| Loss on settlement of lease liability | NaN | NaN | -7 | NaN |
| Reduction in the carrying amount of right-of-use assets | 132 | 158 | 186 | 386 |
| Stock-based compensation | 342 | 289 | 236 | 426 |
| Non-cash interest expense | 130 | 127 | 124 | 240 |
| Allowance for credit losses | -1 | -25 | 13 | -57 |
| Gain on sale of asset held for sale | NaN | 700 | NaN | NaN |
| Change in fair value of warrant liabilities | 219 | -482 | 285 | -702 |
| Loss from termination of operating leases | -1 | -19 | NaN | NaN |
| Accounts receivable | -3,413 | 4,272 | -947 | -1,418 |
| Other receivables, related party | -1 | 68 | -68 | 0 |
| Prepaid expenses and other assets | -1,219 | 1,537 | 236 | -45 |
| Other assets, related party | -25 | -47 | -220 | 953 |
| Inventories | -307 | 872 | 301 | -2,618 |
| Accounts payable | 1,780 | -1,784 | -630 | 2,412 |
| Accounts payable, related parties, net | -3,497 | 2,825 | 1,316 | -4,674 |
| Operating lease liabilities | -10 | -137 | -175 | -371 |
| Accrued expenses and other liabilities | 566 | -1,660 | 746 | 1,524 |
| Cash flows used in operating activities | -70 | -2,376 | -3,823 | -7,162 |
| Sales of investment, related party | NaN | 0 | 0 | 0 |
| Purchase of intangible assets | NaN | 0 | 0 | 0 |
| Proceeds from sale of asset held for sale | NaN | 3,000 | NaN | NaN |
| Payment to extinguish line of credit | NaN | NaN | 0 | 0 |
| Purchases of property and equipment | 5 | -1 | -1 | 4 |
| Proceeds from stockholder advances | NaN | NaN | NaN | 8,500 |
| Cash flows used in investing activities | -5 | 3,001 | 1 | -4 |
| Proceeds from issuance of series b-1 preferred stock and warrants to purchase series b-3 preferred stock, net of issuance costs | NaN | 0 | 0 | 0 |
| Proceeds from issuance of series b-3 preferred stock from exercise of warrants | NaN | 0 | 0 | 0 |
| Payment of principal short-term debt | NaN | 0 | 0 | 0 |
| Proceeds from issuance of series c preferred stock, net of offering costs | NaN | 2,350 | 8,500 | NaN |
| Cash flows provided by financing activities | NaN | 2,350 | 0 | 8,500 |
| Net increase in cash and cash equivalents | NaN | 2,975 | NaN | NaN |
| Net decrease in cash and cash equivalents | -75 | 2,975 | -3,822 | 1,334 |
| Cash, cash equivalents and restricted cash, at the beginning of the period | 6,592 | 3,617 | 6,105 | NaN |
| Cash, cash equivalents and restricted cash, at the end of the period | 6,517 | 6,592 | 3,617 | NaN |
Biofrontera Inc. (BFRI)
Biofrontera Inc. (BFRI)